Sen. Kay Hagan’s draft FDA reform legislation includes several provisions aimed at expanding the pool of possible participants in agency advisory committees.
Adjusting conflict of interest rules for FDA advisory committees has emerged as a high-priority issue to be addressed by Congress...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?